Wendt C, Margolin S. Identifying breast cancer susceptibility genes—a review of the genetic background in familial breast cancer. Acta Oncol. 2019;58(2):135–46.

CAS  PubMed  Google Scholar 

Yadav P, et al. Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients. Clin Transl Oncol. 2016;18(7):728–34.

MathSciNet  CAS  PubMed  Google Scholar 

Xu Y, et al. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023;10(1):334.

PubMed  PubMed Central  Google Scholar 

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

PubMed  Google Scholar 

Arnold M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23.

PubMed  PubMed Central  Google Scholar 

Xu H, Xu B. Breast cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2023;35(6):565.

PubMed  PubMed Central  Google Scholar 

Iacoviello L, et al. Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis. In: Seminars in Cancer biology. Elsevier; 2020.

Miedl H, et al. Association of the MDM2 SNP285 and SNP309 genetic variants with the risk, age at onset and prognosis of breast cancer in Central European women: a hospital-based case-control study. Int J Mol Sci. 2019;20(3):509.

CAS  PubMed  PubMed Central  Google Scholar 

Sha M, Huang X, Yin Q. MiR-548b-3p inhibits proliferation and migration of breast cancer cells by targeting MDM2. Eur Rev Med Pharmacol Sci. 2020;24(6):3105–12.

PubMed  Google Scholar 

Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer: mini review. Growth Factors. 2005;23(3):183–92.

CAS  PubMed  Google Scholar 

Agrawal A, et al. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp Mol Pathol. 2006;81(2):115–22.

MathSciNet  CAS  PubMed  Google Scholar 

Razi B, et al. Association between MTHFR gene polymorphism and susceptibility to autism spectrum disorders: systematic review and meta-analysis. Res Autism Spectr Disord. 2020;70:101473.

Google Scholar 

Fouchécourt S, et al. Apoptosis of Sertoli cells after conditional ablation of murine double minute 2 (Mdm2) gene is p53-dependent and results in male sterility. Cell Death Differ. 2016;23(3):521–30.

PubMed  Google Scholar 

Momand J, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453–9.

CAS  PubMed  PubMed Central  Google Scholar 

Ladanyi M, et al. MDM2 gene amplification in metastatic osteosarcoma. Can Res. 1993;53(1):16–8.

CAS  Google Scholar 

Li X, et al. Competitive ubiquitination activates the tumor suppressor p53. Cell Death Differ. 2020;27:1807–18.

CAS  PubMed  Google Scholar 

Liu B, et al. MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner. Oncogene. 2019;38(14):2501–15.

CAS  PubMed  Google Scholar 

Eslami MM, et al. Factor V Leiden 1691G> a mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis. Thromb J. 2020;18(1):1–16.

Google Scholar 

Surekha D, et al. Codon 72 and G13964C intron 6 polymorphisms of TP53 in relation to development and progression of breast cancer in India. Asian Pac J Cancer Prev. 2011;12(8):1893–988.

CAS  PubMed  Google Scholar 

Mitra S, et al. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol. 2005;58(1):26–31.

CAS  PubMed  PubMed Central  Google Scholar 

Jain N, et al. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest. 2005;128(6):3999–4007.

CAS  PubMed  Google Scholar 

Addala L, et al. P5 3 codon 72 gene polymorphism and risk of Oral squamous cell carcinoma in South Indian population: a case-control study. J Cancer Sci Ther. 2012;4:188–92.

CAS  Google Scholar 

Bond GL, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Can Res. 2006;66(10):5104–10.

CAS  Google Scholar 

Bond GL, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.

CAS  PubMed  Google Scholar 

Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

PubMed  Google Scholar 

Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

PubMed  Google Scholar 

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

CAS  PubMed  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

CAS  PubMed  Google Scholar 

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

CAS  PubMed  Google Scholar 

Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

CAS  PubMed  PubMed Central  Google Scholar 

Akisik E, Yazici H, Dalay N. ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer. Mol Biol Rep. 2011;38(1):343–8.

CAS  PubMed  Google Scholar 

Paulin FE, et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer. 2008;8(1):281.

PubMed  PubMed Central  Google Scholar 

Copson ER, et al. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer. 2006;6(1):80.

PubMed  PubMed Central  Google Scholar 

Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006;240(2):195–7.

CAS  PubMed  Google Scholar 

Krekac D, et al. MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology. 2008;74(1–2):84–7.

CAS  PubMed  Google Scholar 

Knappskog S, et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell. 2011;19(2):273–82.

CAS  PubMed  Google Scholar 

Gansmo LB, et al. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int J Cancer. 2015;137(1):96–103.

CAS  PubMed  Google Scholar 

Yilmaz M, et al. Significant association of the MDM2 T309G polymorphism with breast cancer risk in a Turkish population. Asian Pac j Cancer Prev APJCP. 2018;19(4):1059.

CAS  PubMed  Google Scholar 

Petenkaya A, et al. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res. 2006;26(6C):4975–7.

CAS  PubMed  Google Scholar 

Piotrowski P, et al. Murine double minute clone 2 309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience. Int J Biol Markers. 2012;27(2):105–10.

Google Scholar 

Sinilnikova OM, et al. The TP53 Arg72Pro and MDM2 309G> T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2009;101(8):1456–60.

CAS  PubMed  PubMed Central  Google Scholar 

Wasielewski M, et al. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat. 2007;104(2):153–7.

CAS  PubMed  Google Scholar 

Wilkening S, et al. The single nucleotide polymorphism IVS1+ 309 in mouse double minute 2 does not affect risk of familial breast cancer. Can Res. 2006;66(2):646–8.

CAS  Google Scholar 

Yarden RI, et al. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat. 2008;111(3):497–504.

CAS  PubMed  Google Scholar 

Alshatwi AA, et al. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population. Fundam Clin Pharmacol. 2012;26(3):438–43.

CAS  PubMed  Google Scholar 

Afshari ZT, et al. Lack of an association between a functional polymorphism in the MDM2 promoter and breast cancer in women in northeast Iran. Rep Biochem mol biol. 2017;6(1):112.

CAS  Google Scholar 

Sun Y-F, et al. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer. 2009;9(1):13.

PubMed  PubMed Central  Google Scholar 

Isakova J, et al. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females. BMC Cancer. 2017;17(1):758.

PubMed  PubMed Central